ALVR News and Press, AlloVir Inc. From 06/29/23

2023-06-29 09:29:22 ET Cell therapy developer Allovir, Inc. ( NASDAQ: ALVR ) added ~11% pre-market Thursday after Gilead ( NASDAQ: GILD ) disclosed the purchase of ~$11M worth of company stock. According to an SEC filing on Wednesday, the drugmaker has bought ~2.9M All...

2023-06-29 08:29:48 ET Eco Wave Power  ( WAVE ) +56% . RenovoRx ( RNXT ) +24% . Kintara Therapeutics ( KTRA ) +22% . Intelligent Living Application  ( ILAG ) +15% . Joby Aviation ( JOBY ) +14% rallies 10% to new 52-week h...

2023-06-23 13:56:53 ET Shares of AlloVir (NASDAQ: ALVR) were down 39.8% for the week as of early Friday afternoon, after being down as much as 42.8%, according to data provided by S&P Global Market Intelligence . The clinical-stage biotech's stock is down more than 36% s...

2023-06-22 13:21:19 ET Gainers: TRxADE HEALTH ( MEDS ) +56% . ShiftPixy ( PIXY ) +45% . Root ( ROOT ) +36% . VCI Global Limited ( VCIG ) +34% . Barfresh Food Group ( BRFH ) +27% . Oncolytics Biotech ( ONCY ) +23% . ...

2023-06-22 10:02:12 ET Gainers: TRxADE HEALTH ( MEDS ) +39% . Talaris Therapeutics ( TALS ) +25% . IGM Biosciences ( IGMS ) +11% . Predictive Oncology ( POAI ) +4% . Zymeworks ( ZYME ) +3% . Losers: Innovative Eyewear...

2023-06-22 05:56:22 ET Stock futures inched down during Thursday's premarket activity after the market lost ground for three straight days. Jerome Powell, the chairman of the US Federal Reserve, issued a warning on Wednesday about the need for more interest rate increases to combat inflatio...

2023-06-22 02:45:10 ET AlloVir ( NASDAQ: ALVR ) is down 21.3% after-hours on Wednesday after the firm has priced an underwritten public offering of 20M shares of its common stock at a price of $3.75/share. Gross proceeds are expected to be $75.0M. All shares in th...

AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $3.75 per share. The gross proceeds to AlloVir from the offering, before deducting underw...

2023-06-21 16:36:58 ET AlloVir ( NASDAQ: ALVR ) said Wednesday it plans to undertake a public offering of $75 million of its common stock. Underwriters have a 30-day option to purchase up to an additional 15% of the shares being offered. All of the shares in the ...

AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that it has commenced a proposed underwritten public offering of $75.0 million of shares of its common stock. AlloVir also intends to grant the underwriters a 30-day option to purchase up to an additional 15...